| Product Code: ETC9464933 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview |
3.1 Sri Lanka Country Macro Economic Indicators |
3.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, 2021 & 2031F |
3.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Industry Life Cycle |
3.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Porter's Five Forces |
3.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.7 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) among healthcare professionals in Sri Lanka. |
4.2.2 Growing prevalence of autoimmune diseases and neurological disorders in the country. |
4.2.3 Advancements in medical technology and treatment options for CIDP patients. |
4.3 Market Restraints |
4.3.1 Limited access to specialized healthcare facilities and neurologists in certain regions of Sri Lanka. |
4.3.2 High cost of CIDP treatments and medications, impacting affordability for patients. |
4.3.3 Lack of standardized guidelines and protocols for CIDP management in the country. |
5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends |
6 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Types |
6.1 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous Immunoglobulin, 2021- 2031F |
6.1.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Plasmapheresis, 2021- 2031F |
6.1.6 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Physiotherapy, 2021- 2031F |
6.1.7 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Diagnosis |
6.2.1 Overview and Analysis |
6.2.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Electrodiagnostic Testing, 2021- 2031F |
6.2.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Nerve Conduction, 2021- 2031F |
6.2.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By EMG, 2021- 2031F |
6.2.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Spinal Fluid Analysis, 2021- 2031F |
6.2.6 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.3.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
7 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Import-Export Trade Statistics |
7.1 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Export to Major Countries |
7.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Imports from Major Countries |
8 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis for CIDP patients in Sri Lanka. |
8.2 Number of neurologists specializing in CIDP per capita in the country. |
8.3 Percentage of CIDP patients receiving recommended treatments according to guidelines. |
8.4 Patient-reported outcomes related to quality of life improvements post-treatment. |
8.5 Level of patient and caregiver education and awareness programs effectiveness. |
9 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Opportunity Assessment |
9.1 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.3 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Competitive Landscape |
10.1 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue Share, By Companies, 2024 |
10.2 Sri Lanka Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here